Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Arm, Multicenter, Phase 2 Study of Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Next Previous
X
Search
Trial Profile

A Single-Arm, Multicenter, Phase 2 Study of Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brigatinib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms J-ALTA
  • Sponsors Takeda

    • Most Recent Events

    • 01 Sep 2023 Results of Exploratory analysis assessing the efficacy and safety of brigatinib in Japanese patients with advanced ALK+ non-small-cell lung cancer published in the Cancer Science
    • 06 Jun 2023 Results of pooled analysis from ALTA-1L and J-ALTA , presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 13 Sep 2022 Results of pooled analysis from NCT03535740 and NCT03410108 of exploratory integrated analysis of the impact of EML4-ALK fusion and secondary ALK mutations on efficacy with brigatinib in alectinib-refractory ALK+ NSCLC patients, presented at the 47th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top